TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04613635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stratafix
Description: Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Stratafix USP (United States Pharmacopoe) 2-0 thread

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl
Description: Closure of ventral defect of the otherwise stapled gastrojejunal anastomosis with Vicryl USP 2-0 thread
Study: NCT04054895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lead placed in the His-Purkinje system in order to achieve QRS shortening.
Description: Physiologic pacing to achieve QRS shortening. If the patient has indication of stimulation (AV block), a backup lead will be implanted in the right ventricle. All patients will have a lead placed in the right atrium (except those that have permanent atrial fibrillation).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lead is placed in a tributary of the coronary sinus.
Description: Biventricular Resynchronization Therapy is the use of a pacemaker with two endocardial leads placed in the right atrium and right ventricle. The third lead is placed in a tributary of the coronary sinus.
Study: NCT03215121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One handed mask airway, switch to two hands
Description: Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand mask airway with switch to two hand for Group 1 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds.
Study: NCT03054727

Intervention type: OTHER
Intervention: Villalta phone score > or = to 5
Description: Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination.

Intervention type: OTHER
Intervention: Villalta phone score > or = to 5
Description: Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \> or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.~All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination.

Intervention type: OTHER
Intervention: Villalta phone score < 5
Description: Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires.

Intervention type: OTHER
Intervention: Villalta phone score < 5
Description: Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score \< 5, will don't have a clinical follow up.~All patients will have self administered-questionnaires.
Study: NCT02770287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Freeze Diamond Polar
Description: The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system that combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
Study: NCT02017249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine in powder form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silica and cellulose placebo powder
Study: NCT02795767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered as per the schedule specified in the respective arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered as per the schedule specified in the respective arm.
Study: NCT03215121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two handed mask airway + jaw thrust
Description: Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two handed mask airway, switch to one hand
Description: Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.~Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, two hands for Group 3 patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.~After another 20 seconds (50 seconds from the start of induction), in Group 3, the mask holding will switch to one hand for 20 seconds.
Study: NCT02564055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% Cream
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 1% Cream
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 0.5% Cream
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2894512 0.5% Cream
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: White to off-white vehicle cream base to be applied topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: White to off-white vehicle cream base to be applied topically
Study: NCT03950219

Intervention type: OTHER
Intervention: Group course
Description: Education and support
Study: NCT04420689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALM-488
Description: ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALM-488
Description: ALM-488 Sterile Solution is an intravenously administered, synthetic, peptide dye conjugate indicated for the real-time intraoperative fluorescence detection and localization of nerve tissue.
Study: NCT04592536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865 High dose
Description: High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam 1mg XR
Description: Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral tablet/capsule will be administered for 8 days BID (morning dose only on 8th day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL-865 low dose
Description: Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
Study: NCT03371186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health Worker
Description: The intervention is designed to address these primary drivers of underutilization of reproductive, maternal, newborn, and child health services in rural Nepal, namely: poverty, lack of social support, and poor birth planning. The investigators have worked with a cadre of Community Healthcare Workers who, in addition to the responsibilities of local community health volunteers, have added responsibilities, training, and managerial support. These women support their community members in their homes to identify and overcome social barriers and plan for emergency healthcare needs. The goals are to increase utilization of services, maternal and neonatal health knowledge, self-efficacy, social support, and emergency planning among mothers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Surveillance
Description: Each patient identified by a Community Health Worker will undergo a complete diagnostic evaluation by the hospital-based clinicians and will be enrolled in the study only if they are identified as currently pregnant, have recently given birth, or have a child under the age of 24 months. Continuous surveillance systems ensure that the entire population is surveyed every three months and has a three month touchpoint with a Community Health Worker.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CB-Integrated Management of Newborn and Childhood Illness
Description: Safe delivery care; effective neonatal resuscitation; management of childhood diarrhea, malnutrition, and pneumonia; and treatment of traumatic and congenital surgical conditions can reduce child mortality. Community Based Integrated Management of Newborn and Child Illness (CB-IMNCI) has shown substantial reductions in neonatal and early child mortality. Community Health Workers will use CB-IMNCI as the clinical protocol for ongoing care to the community.
Study: NCT02795767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emicizumab
Description: Emicizumab will be administered as per the schedule specified in the respective arm.
Study: NCT01348919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-18770
Description: CEP-18770 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-18770
Description: CEP-18770 will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-18770
Description: CEP-18770 will be administered per dose and schedule specified in the arm description.
Study: NCT03371186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Antenatal and Postnatal Care
Description: The proposed model will change antenatal and pediatric care in three major ways: 1) conduct care in a group setting, 2) provide expert and facilitated peer counseling, and 3) incorporate emergency planning. The group setting is designed to create a supportive social network among women facing similar challenges. The opportunity for counseling beyond the current standard will promote detailed emergency planning and the sharing of context-specific advice from peers to overcome barriers to access care. This intervention draws on the strength within communities of women to change health-seeking behaviors.
Study: NCT00467142

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT01348919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered per dose and schedule specified in the arm description.
Study: NCT03371186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced Post-Partum Contraceptive Counseling
Description: Research on interventions to improve postpartum contraception suggest strategies that bridge the continuum of reproductive health care-antenatal care, labor and delivery, postnatal care, and infant care-are more effective than short term, stand-alone counseling sessions. The structured counseling module incorporated in the intervention will be partially adapted from the Balanced Counseling Strategy, an interactive contraceptive counseling method developed by the Population Council in accordance with the World Health Organization's tiered effectiveness guidelines. Prior studies in clinical settings in Nepal have demonstrated increased uptake of modern contraceptive methods, especially of long-acting reversible contraceptives with use of balanced counseling.
Study: NCT02679729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
Study: NCT01348919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered per dose and schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered per dose and schedule specified in the arm description.
Study: NCT00715897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Description: 8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
Study: NCT02679729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for inhalation
Description: Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634 for infusion
Description: Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inactive substance
Study: NCT03999645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early laparoscopic cholecystectomy
Description: within 72h from symptom onset

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late laparoscopic cholecystectomy
Description: after 72h up to seven days from symptom onset
Study: NCT00467142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01787695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UVA1
Description: Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.~The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment.
Study: NCT00467142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study: NCT02315963

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Performance Feedback
Description: Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
Study: NCT02385708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorohexidine Gluconate Standard of Care
Description: Patients will perform the current standard of care treatment using 2% Chlorohexidine Gluconate Cloths on the abdomen and buttocks prior to colorectal surgery night before surgery and morning of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorohexidine Gluconate Chin to Toe
Description: Patients will perform treatment with 2% Chlorohexidine Gluconate cloths chin to toe night before and morning of surgery then daily post operative until post op day 4 or discharge
Study: NCT00961376

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PBMC re-infusion
Description: Autologous PBMC re-infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD25 depletion
Description: Autologous, CD25-depleted PBMC re-infusion
Study: NCT02734511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sedation with propofol
Description: induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
Study: NCT04212845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine;Dexamethasone Solution for Injection
Description: 8 mg Dexamethasone and %0.25 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine;Dexamethasone Solution for Injection
Description: 8 mg Dexamethasone and %0.25 bupivacaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: Fluoroscopy-guided transforaminal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided erector spinae plane block
Study: NCT00467142

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Study: NCT04037384

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eye yoga
Description: Eye yoga exercises at home given by a trained instructor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive Reading
Description: Passive reading at home
Study: NCT02802683

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: spinal anesthesia with hyperbaric bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: spinal anesthesia with hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: spinal anesthesia with isobaric levobupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: spinal anesthesia with isobaric levobupivacaine
Study: NCT01413646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Walnut Supplementation
Description: Eight weeks of walnut supplementation
Study: NCT02802683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: continous infusion of phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: continous infusion of phenylephrine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: continous infusion of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: continous infusion of normal saline
Study: NCT01413646

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No walnut supplementation
Description: Eight weeks without walnut supplementation
Study: NCT00353574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan capsules administered orally once daily
Study: NCT03197272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PiXL
Description: Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
Study: NCT02614664

Intervention type: DEVICE
Intervention: NIRS
Description: Cerebral oxygenation monitor which is standard of care for this surgery.